Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2004 1
2006 1
2007 1
2008 2
2009 5
2010 6
2011 5
2012 4
2013 6
2014 4
2015 3
2016 3
2017 1
2020 6
2021 11
2022 13
2023 12
2024 4
2025 12
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. Del Bufalo F, et al. Among authors: de ioris ma. N Engl J Med. 2023 Apr 6;388(14):1284-1295. doi: 10.1056/NEJMoa2210859. N Engl J Med. 2023. PMID: 37018492
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Locatelli F, Pagliara D, De Ioris MA, Becilli M, Del Baldo G, Serra A, Mastronuzzi A, Cefalo MG, Li Pira G, Leone G, Bertaina V, Fabozzi F, Di Nardo M, Rosignoli C, D'Andrea ML, Crocoli A, Vennarini S, Sinibaldi M, Di Cecca S, Guercio M, Iaffaldano L, Lucarelli B, Algeri M, Merli P, Colafati GS, De Angelis B, Quintarelli C, Del Bufalo F. Locatelli F, et al. Among authors: de ioris ma. Nat Med. 2025 Nov;31(11):3689-3699. doi: 10.1038/s41591-025-03874-6. Epub 2025 Aug 21. Nat Med. 2025. PMID: 40841488 Clinical Trial.
Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma.
Tempora P, D'Amico S, Gragera P, Damiani V, Krol K, Scaldaferri V, Pandey K, Chung S, Lucarini V, Giorda E, Scarsella M, Volpe G, Pezzullo M, De Stefanis C, D'Oria V, De Angelis L, Giovannoni R, De Ioris MA, Melaiu O, Purcell AW, Locatelli F, Fruci D. Tempora P, et al. Among authors: de ioris ma. J Exp Clin Cancer Res. 2024 Oct 22;43(1):292. doi: 10.1186/s13046-024-03180-y. J Exp Clin Cancer Res. 2024. PMID: 39438988 Free PMC article.
Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma.
Quintarelli C, Del Bufalo F, De Ioris MA, Guercio M, Algeri M, Pagliara D, Silvestris DA, Di Nardo M, Sinibaldi M, Di Cecca S, Iaffaldano L, Manni S, Fustaino V, Garganese MC, Colafati GS, Bertaina V, Becilli M, Mastronuzzi A, Fabozzi F, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Li Pira G, Cefalo MG, Leone G, Del Baldo G, De Angelis B, Locatelli F. Quintarelli C, et al. Among authors: de ioris ma. Nat Med. 2025 Mar;31(3):849-860. doi: 10.1038/s41591-024-03449-x. Epub 2025 Jan 15. Nat Med. 2025. PMID: 39815015
Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Locatelli F, Pagliara D, De Ioris MA, Becilli M, Del Baldo G, Serra A, Mastronuzzi A, Cefalo MG, Li Pira G, Leone G, Bertaina V, Fabozzi F, Di Nardo M, Rosignoli C, D'Andrea ML, Crocoli A, Vennarini S, Sinibaldi M, Di Cecca S, Guercio M, Iaffaldano L, Lucarelli B, Algeri M, Merli P, Colafati GS, De Angelis B, Quintarelli C, Del Bufalo F. Locatelli F, et al. Among authors: de ioris ma. Nat Med. 2025 Nov;31(11):3933. doi: 10.1038/s41591-025-03996-x. Nat Med. 2025. PMID: 40926103 No abstract available.
Mapping B cells and the immune landscape of tertiary lymphoid structures reveals their clinical impact in neuroblastoma.
Melaiu O, Chierici M, Gragera P, Lazzaro N, Petrilli LL, Wienke J, Bergsma FJ, Verhoeven BM, De Stefanis C, D'Oria V, Benedetti MC, Barillari G, Alaggio R, De Ioris MA, Vinci M, Baryawno N, Carsetti R, Jurman G, Molenaar JJ, Locatelli F, Fruci D. Melaiu O, et al. Among authors: de ioris ma. J Immunother Cancer. 2025 Nov 11;13(11):e012860. doi: 10.1136/jitc-2025-012860. J Immunother Cancer. 2025. PMID: 41218854 Free PMC article.
Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma.
Lucarini V, Melaiu O, D'Amico S, Pastorino F, Tempora P, Scarsella M, Pezzullo M, De Ninno A, D'Oria V, Cilli M, Emionite L, Infante P, Di Marcotullio L, De Ioris MA, Barillari G, Alaggio R, Businaro L, Ponzoni M, Locatelli F, Fruci D. Lucarini V, et al. Among authors: de ioris ma. J Exp Clin Cancer Res. 2022 Nov 17;41(1):326. doi: 10.1186/s13046-022-02525-9. J Exp Clin Cancer Res. 2022. PMID: 36397148 Free PMC article.
131I-mIBG therapy in relapsed/refractory neuroblastoma: A weapon from the future past.
Fabozzi F, Villani MF, Del Bufalo F, Altini C, Cannatà V, Davide C, Pizzoferro M, Drago M, D'Antonio F, Triumbari EKA, Di Giannatale A, Vennarini S, Mastronuzzi A, De Ioris MA, Garganese MC. Fabozzi F, et al. Among authors: de ioris ma. Crit Rev Oncol Hematol. 2025 Mar;207:104606. doi: 10.1016/j.critrevonc.2024.104606. Epub 2024 Dec 26. Crit Rev Oncol Hematol. 2025. PMID: 39732302
131I-mIBG therapy in relapsed/refractory neuroblastoma: an old bridge to the future.
De Ioris MA, Villani MF, Fabozzi F, Del Bufalo F, Altini C, Cefalo MG, Cannata V, Del Baldo G, Pizzoferro M, Alessi I, Lanzaro F, Davide C, Tomà P, D'Andrea ML, Di Giannatale A, Serra A, Mastronuzzi A, Garganese MC, Locatelli F. De Ioris MA, et al. ESMO Open. 2025 Apr;10(4):104541. doi: 10.1016/j.esmoop.2025.104541. Epub 2025 Apr 4. ESMO Open. 2025. PMID: 40187111 Free PMC article.
93 results